The Federal Trade Commission reached a settlement with Amgen that would allow the drugmaker to acquire Horizon Therapeutics and dismisses the antitrust claims of six states.
Amgen says it expects to quickly seek the final approval needed to close its transaction for Horizon Therapeutics.
WASHINGTON—The Federal Trade Commission said Friday it reached an agreement that would end its legal challenge of drugmaker, averting a trial that was to have started this month.Continue reading your article with
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisitionThe FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would 'stifle competition' in the pharmaceutical industry.
続きを読む »
FTC settles with Amgen over $27.8 billion takeover of Horizon TherapeuticsThe Federal Trade Commission reached a deal with Amgen Inc. to approve its $27.8 billion acquisition of Horizon Therapeutics plc, the agency announced...
続きを読む »
FTC Settles With Amgen Over $27.8 Billion Deal for Horizon TherapeuticsThe Federal Trade Commission reached a settlement with Amgen that would allow the drugmaker to acquire Horizon Therapeutics and dismisses the antitrust claims of six states.
続きを読む »
Amgen and Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion MergerThe Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications.
続きを読む »